Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting EML4-ALK gene fusion variant 3 in thyroid cancer

20 Apr 2021

Abstract excerpt

Finding targetable gene fusions can expand the limited treatment options in radioactive iodine-refractory (RAI-r) thyroid cancer. To that end, we established a novel cell line 'JVE404' derived from an advanced RAI-r papillary thyroid cancer (PTC) patient, harboring an EML4-ALK gene fusion variant 3 (v3). Different EML4-ALK gene fusions can have different clinical repercussions. JVE404 cells were evaluated for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Lung Cancer Treatments and Mutations
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33878728
DOI: 10.1530/erc-20-0436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting EML4-ALK gene fusion variant 3 in thyroid cancerPMID 33878728Read ↗

Case Report of CCDC149-ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter studySemantic proximity Read ↗

Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinomaSemantic proximity Read ↗

Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid CancerSemantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR) Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid CancerSemantic proximity Read ↗

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Semantic proximity Read ↗

Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the <i>ALK</i> GeneSemantic proximity Read ↗

NTRK and RET fusion–directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptakeSemantic proximity Read ↗

Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.